Inspira Technologies Oxy B.H.N. Ltd Stock

$0.51

0.16% yesterday

Nasdaq, May 20, 10:00 pm CET

ISIN

IL0011715781

Symbol

IINN

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Medical specialties

Overview Dividends Analysts Charts News Strategies

Inspira Technologies Oxy B.H.N. Ltd Stock price

$0.51

-4.24 89.26% 5Y

Nasdaq, Closing price Tue, May 20 2025

+0.00 0.16%

ISIN

IL0011715781

Symbol

IINN

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Medical specialties

Key metrics

Market capitalization	$13.07m
Enterprise Value	$9.43m
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	negative
P/B ratio (TTM) P/B ratio	2.86
Revenue (TTM) Revenue	$0.00
EBIT (operating result TTM) EBIT	$-11.26m
Free Cash Flow (TTM) Free Cash Flow	$-9.54m
Cash position	$7.36m
EPS (TTM) EPS	$-0.60
Short interest	0.35%

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Get Started for Free Today

Inspira Technologies Oxy B.H.N. Ltd Stock Analysis

Unlock Scores for Free

??

1 Analyst has issued a forecast Inspira Technologies Oxy B.H.N. Ltd:

1x Buy

100%

More details on Analyst Estimates Including Price Targets

1 Analyst has issued a forecast Inspira Technologies Oxy B.H.N. Ltd:

Buy

100%

Analyst Estimates with Stock Price Targets

Financial data from Inspira Technologies Oxy B.H.N. Ltd

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Dec '24		+/- %
Revenue	- -	- 100%
- Direct Costs	0.49 0.49	- -
Gross Profit	-0.49 -0.49	- -
- Selling and Administrative Expenses	4.33 4.33	10% 10% -
- Research and Development Expense	5.95 5.95	19% 19% -
EBITDA	-11 -11	- -
- Depreciation and Amortization	0.49 0.49	- -
EBIT (Operating Income) EBIT	-11 -11	7% 7% -
Net Profit	-11 -11	2% 2% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Inspira Technologies Oxy B.H.N. Ltd Stock News

Neutral

GlobeNewsWire

●

14 days ago

INSPIRA ART100 System Approved by Israel's Largest Healthcare Provider for Use in Organ Transplant Patients

RA'ANANA, Israel, May 07, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced that the INSPIRA™ ART100 has been approved by Israel's largest healthcare provider to undergo a clinical validation by leading physicians who intend to use the innovative life-suppo...

Neutral

GlobeNewsWire

●

28 days ago

Inspira Achieves above 99% Gas Exchange Efficiency in VORTX™ Technology In-Vivo Animal Testing

RA'ANANA, Israel, April 23, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced a major milestone achievement in the in-vivo testing of its next-generation VORTX™ technology.

Neutral

GlobeNewsWire

●

about one month ago

Inspira Technologies Generates First Revenues from Deployment of INSPIRA ART100 Systems

The Company achieves significant milestone with initial revenues generated from FDA-cleared life support technology deployed in a leading U.S. healthcare facility; additional systems currently planned for second hospital facility The Company achieves significant milestone with initial revenues generated from FDA-cleared life support technology deployed in a leading U.S. healthcare facility; add...

More Inspira Technologies Oxy B.H.N. Ltd News

Company Profile

Inspira Technologies Oxy B.H.N. Ltd. engages in research, development, manufacture, and marketing of proprietary respiratory support technology. The firm seeks to provide alternative to invasive mechanical ventilation. The company was founded in July 2017 and is headquartered in Raanana, Israel.

Head office	Israel
CEO	Dagi Ben-Noon
Employees	48
Founded	2017
Website	www.inspira-technologies.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now